Both GLP-1 receptor agonist and SGLT2 inhibitor cohorts had higher average HbA1c values (GLP-1 7.4 ± 2.2, SGLT2 7.6 ± 2.3, non-users 6.9 ± 2.0) and were less likely to have a history of cerebral infarction (GLP-1 3.5%, SGLT2 4.3%, non-users 6.3%). Here, GLP1R is linked to brain infarction.